HIMS

Hims & Hers Health, Inc. (NYSE: HIMS) is a San Francisco-based telehealth company founded in 2017. It offers a direct-to-consumer platform that connects patients with licensed healthcare providers for a range of services, including sexual health, hair loss, mental health, dermatology, and weight management. The company began by addressing men's health issues and later expanded to include women's health through its "Hers" brand. In 2024, Hims & Hers entered the weight-loss market by offering compounded semaglutide, a generic version of the popular drug Wegovy, during a national shortage. This move significantly boosted its stock price and subscriber base. However, after the FDA declared the shortage over in early 2025, the company faced regulatory challenges and stock volatility. Despite these hurdles, Hims & Hers continues to adapt, recently partnering with Novo Nordisk to offer discounted Wegovy, and remains a prominent player in the evolving telehealth landscape. As of May 2, 2025, Hims & Hers Health's stock price is $40.82. Over the past 52 weeks, the stock has reached a high of $72.98 and a low of $11.20. Benzinga+6StockInvest+6Macrotrends+6Macrotrends+8INDmoney+8Hims Inc.+8

Regarding analyst ratings, out of 13 Wall Street analysts, 3 have issued "Buy" ratings, 8 have "Hold" ratings, and 2 have "Sell" ratings for HIMS stock. MarketBeat

Subscribe to our API. See Strong Buy and Sell Signals the Day after They Occur!